Dec 6th, 2018 - The simple blood test costs about $2 and has an accuracy of 99%.
Dec 6th, 2018 - The EUTOS long-term survival score (ELTS) better discriminates patients for risk stratification than the standard Sokal score, according to findings from an analysis of data from 904 patients treated with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) who had enrolled in 6 multicenter studies.
Dec 6th, 2018 - Six new Clinical Practice Guidelines on Venous Thromboembolism have just been announced.
Dec 6th, 2018 - Each year, ASH’s Choosing Wisely Champions Initiative recognizes three practitioners who are working to eliminate costly and potentially harmful overuse of tests and procedures.
Dec 6th, 2018 - The plenary scientific session is a highlight of the annual meeting, where attendees hear presentations of the 6 highest caliber scientific abstracts.
Dec 6th, 2018 - A preview of the Late Breaking Abstracts and The Best of ASH.
Dec 6th, 2018 - The society continues to grow its international influence and help improve hematologic care around the globe.
Dec 6th, 2018 - A look ahead to 2019, with ASH President-Elect, Dr. Roy Silverstein
Dec 6th, 2018 - A look at some of the dynamic scientific panels and presentations including the new frontier of glycobiology and new insights into neonatal hematology
Dec 6th, 2018 - Scientific spotlight sessions at the ASH annual meeting provided an in-depth review of specific scientific topics.
Dec 6th, 2018 - ASH is developing new clinical practice guidelines on the management of acute and chronic complications of sickle cell disease
Dec 5th, 2018 - The combination of ibrutinib and rituximab provided superior progression-free survival and, after follow-up, superior overall survival, compared with the current standard of care, chemoimmunotherapy (CIT) fludarabine, cyclophosphamide, and rituximab (FCR), in treatment-naive patients younger than 70 years with chronic lymphocytic leukemia (CLL), according to research presented at a late-breakin...
Dec 5th, 2018 - A rituximab biosimilar demonstrated noninferiority to European (EU)-licensed rituximab (MabThera) in a randomized trial involving patients with low-tumor burden follicular lymphoma
Dec 5th, 2018 - In the MAIA study, adding the monoclonal antibody daratumumab (Darzalex, Janssen) to standard therapy significantly extended progression-free survival (PFS) in patients newly diagnosed with multiple myeloma who were ineligible for stem cell transplant.
Dec 5th, 2018 - The results of a follow-up analysis to the phase III MAVORIC study were presented at the ASH 2018 Annual Meeting & Exposition.
Dec 5th, 2018 - The CASSINI trial evaluates VTE prophylaxis in ambulatory patients receiving systemic therapy.
Dec 5th, 2018 - Adding daratumumab to standard treatment with lenalidomide and dexamethasone (DRd) reduced the risk of progression or death by 44% among patients with transplant-ineligible newly-diagnosed multiple myeloma, according to an interim analysis of data from the randomized, open-label, multicenter phase 3 MAIA clinical trial
Dec 4th, 2018 - Minimal residual disease and mutational clearance were seen in a significant proportion of patients.
Dec 4th, 2018 - A closely watched trial of venous thromboembolism (VTE) prevention with an oral anticoagulant in cancer patients fell short of a clear win, but not because the drug didn't work, according to a report here.
Dec 4th, 2018 - Tait D. Shanafelt, MD, of Stanford University, discusses phase III study findings on ibrutinib-based therapy vs standard fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy